New 4,000 sq.ft. facility becomes
4th medical cannabis clinic in Bogota
- Khiron opens its 4th Zerenia-branded medical cannabis
clinic in the city of Bogota
- The new clinic, with a capacity of up to 40,000 consults per
year could add 20% to the existing capacity in Colombia
- Located in Plaza Central, one of Bogota's busiest shopping centers with more
than 150,000 visitors per month
- Adjacent to referral locations of 4 of the largest insurance
companies in Colombia
- Continues Khiron's unique patient acquisition strategy through
its Zerenia™ clinic network. In 2021, the Company sold more than
51,800 medical cannabis units in Colombia, up more than 900% from 2020
TORONTO, Jan. 31, 2022 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated
cannabis leader with core operations in Latin America and Europe, today announced the grand opening of
its new medium-sized medical cannabis clinic under its Zerenia™
brand, in the city of Bogota in
Colombia. The new clinic is
strategically located in the heart of the 8 million people city in
one of its busiest shopping centers, next to 4 of Colombia's largest insurance companies.
The new location, named Zerenia™ Americas, has an area of 4,000
sq.ft. It includes 11 consult rooms, with a maximum capacity of
40,000 annual consults, and will expand Khiron's patient capacity
to more than 20% in Colombia.
"We are very excited about this new Zerenia™ format and our
ability to treat more patients and create closer relationships with
insurance companies in Colombia.
Our Zerenia™ clinic network now has more than 13 locations in
Colombia, Peru, and the UK, and we will soon open new
locations worldwide. Our unique strategy has allowed us to grow
medical cannabis sales by more than 900% in Colombia in 2021, increasing patient
conversion and retention rates. The selection of this new location
follows a deep desire to be closer to our patients and offer
insurance companies better access for their patients while
maintaining the service standards that are making Zerenia™ a
leading global medical cannabis clinic network.", commented
Alvaro Torres, Khiron CEO, and
Director. "Now that the Colombian Government has mandated medical
cannabis to be covered by all insurance companies, we believe this
new location strategy will continue to drive great growth and
profitability for Khiron, and will continue to allow us to improve
the quality of life of more patients", added Mr. Torres.
Khiron engages Arrowhead Business and Investment Decisions,
LLC to provide Investor Relations Services
The Company is also pleased to announce that it has retained
Arrowhead Business and Investment Decisions, LLC ("Arrowhead") to
provide investor relations services and develop its international
market awareness. Arrowhead will work closely with Khiron to
develop and deploy a comprehensive international investor marketing
program, which will include the publication of independent
analysis, investor targeting, corporate disclosure distribution,
non-deal roadshows, reporting and strategic advisory. Arrowhead is
a leading US-based investor relations firm which is headquartered
in New York City and was
established in 2008. Arrowhead advises public companies on investor
relations, financial communications, and capital markets
strategies. As a cross-border specialist, Arrowhead provides idea
generation, insight, and corporate access to an international
network of institutional and private investors. Through targeting,
research and interactions, Arrowhead helps corporations and
investors to evaluate opportunities, connect, exchange information,
and transact.
Arrowhead will provide services for an initial committed
six-month term. Cash compensation for the services will be
USD$50,000. Arrowhead is not related
to the Company and has no interest, directly or indirectly, in the
Company or its securities. The engagement of Arrowhead remains
subject to the approval of the TSX Venture Exchange.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated international medical cannabis company with
core operations in Latin America
and Europe. Leveraging
wholly-owned medical health clinics and proprietary telemedicine
platforms, Khiron combines a patient-oriented approach, physician
education programs, scientific expertise, product innovation, and
agricultural infrastructure to drive prescriptions and brand
loyalty with patients worldwide. The Company has a sales presence
in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Peter
Leis
Europe Communications
E: pleis@khiron.ca
Carolina Gomez
Latam
Communications
E: mgomez@khiron.ca
Khiron Europe:
Franziska Katterbach, President
E: fkatterbach@khiron.ca
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-opens-new-medical-cannabis-clinic-in-colombia-301471395.html
SOURCE Khiron Life Sciences Corp.